Diabetic gastroparesis symptoms

When the stomach empties more slowly than normal, such as in people with diabetic gastroparesis, a variety of uncomfortable symptoms may result. If untreated, these can lead to additional health complications. Fortunately, the symptoms of diabetic gastroparesis are treatable.

Diabetic gastroparesis symptoms may include

Nausea
Vomiting—Many people with diabetic gastroparesis vomit repeatedly several hours after eating
Bloating immediately after a meal—These feelings of fullness may develop even after eating small amounts of food
Weight loss and dehydration—Feeling full after eating small amounts of food may make it difficult to consume healthy amounts of food and water. This can lead to weight loss and dehydration
Early satiety—Feeling full soon after you start eating or after eating a small amount of food
Decreased appetite
Heartburn
Abdominal pain

If you are diabetic and are experiencing any of these symptoms, talk to your healthcare professional. He or she can perform tests to determine if you have diabetic gastroparesis and prescribe the right medicine for you.

Metozolv ODT treats diabetic gastroparesis symptoms

Metozolv ODT provides a convenient treatment for diabetic gastroparesis symptoms. It’s an orally disintegrating metoclopramide tablet6 that rapidly* melts on the tongue, which means you can take it anywhere, without liquid. Talk to your healthcare professional to learn more about Metozolv ODT.

Is Metozolv ODT right for you? Discover valuable tools and resources about diabetic gastroparesis, refractory GERD, and Metozolv ODT Learn diet tips that may help improve symptoms of diabetic gastroparesis

*Metozolv ODT disintegrates on the tongue in a median of 53.5 seconds (mean ± standard deviation, 76.8 ± 110.6 seconds).6

References: 1. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463-467. 2. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7:25-32. 3. Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96;444-446. 4. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care. 1993;16:1511-1514. 5. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230-1234. 6. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.

IMPORTANT SAFETY INFORMATION

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms; neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience withdrawal symptoms after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Please see accompanying full Prescribing Information for Metozolv ODT, including BOXED WARNING.